Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hasseli, Rebecca [VerfasserIn]   i
 Richter, Jutta G. [VerfasserIn]   i
 Hoyer, Bimba Franziska [VerfasserIn]   i
 Lorenz, Hanns-Martin [VerfasserIn]   i
 Pfeil, Alexander [VerfasserIn]   i
 Regierer, Anne Constanze [VerfasserIn]   i
 Schmeiser, Tim [VerfasserIn]   i
 Strangfeld, Anja [VerfasserIn]   i
 Voll, Reinhard E. [VerfasserIn]   i
 Krause, Andreas [VerfasserIn]   i
 Reckert, Sabine [VerfasserIn]   i
 Gräßler, Anett [VerfasserIn]   i
 Saar, Petra [VerfasserIn]   i
 Kapelle, Andreas [VerfasserIn]   i
 Backhaus, Marina [VerfasserIn]   i
 Blank, Norbert [VerfasserIn]   i
 Henes, Joerg [VerfasserIn]   i
 Osiek, Silke [VerfasserIn]   i
 Knothe, Anna [VerfasserIn]   i
 Hoese, Guido [VerfasserIn]   i
 Brandt-Jürgens, Jan [VerfasserIn]   i
 Maltzahn, Anja [VerfasserIn]   i
 Specker, Christof [VerfasserIn]   i
 Müller-Ladner, Ulf [VerfasserIn]   i
 Schulze-Koops, Hendrik [VerfasserIn]   i
Titel:Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
Verf.angabe:Rebecca Hasseli, Jutta G. Richter, Bimba Franziska Hoyer, Hanns-Martin Lorenz, Alexander Pfeil, Anne Constanze Regierer, Tim Schmeiser, Anja Strangfeld, Reinhard E. Voll, Andreas Krause, Sabine Reckert, Anett Gräßler, Petra Saar, Andreas Kapelle, Marina Backhaus, Norbert Blank, Joerg Henes, Silke Osiek, Anna Knothe, Guido Hoese, Jan Brandt-Jürgens, Anja Maltzahn, Christof Specker, Ulf Müller-Ladner, Hendrik Schulze-Koops, COVID-19 task force of the German Society of Rheumatology collaborators
E-Jahr:2023
Jahr:April 17, 2023
Umfang:11 S.
Fussnoten:Gesehen am 26.06.2023
Titel Quelle:Enthalten in: RMD Open
Ort Quelle:London : BMJ Publishing Group, 2015
Jahr Quelle:2023
Band/Heft Quelle:9(2023), 2 vom: Apr., Artikel-ID e002998, Seite 1-11
ISSN Quelle:2056-5933
Abstract:Objective: To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs). - Methods: Data from the physician-reported German COVID-19-IRD registry collected between February 2021 and July 2022 were analysed. SARS-CoV-2 cases were stratified according to patients’ vaccination status as being not vaccinated, double-vaccinated or triple-vaccinated prior to SARS-CoV-2 infection and descriptively compared. Independent associations between demographic and disease features and outcome of breakthrough infections were estimated by multivariable logistic regression. - Results: In total, 2314 cases were included in the analysis (unvaccinated n=923, double-vaccinated n=551, triple-vaccinated n=803, quadruple-vaccinated n=37). SARS-CoV-2 infections occurred after a median of 151 (range 14-347) days in patients being double-vaccinated, and after 88 (range 14-270) days in those with a third vaccination. Hospitalisation was required in 15% of unvaccinated, 8% of double-vaccinated and 3% of triple-vaccinated/quadruple-vaccinated patients (p<0.001). Mortality was 2% in unvaccinated, 1.8% in the double-vaccinated and 0.6% in triple-vaccinated patients. Compared with unvaccinated patients, double-vaccinated (OR 0.43, 95% CI 0.29 to 0.62) and triple-vaccinated (OR 0.13, 95% CI 0.08 to 0.21) patients showed a significant lower risk of COVID-19-related hospitalisation. Using multivariable analysis, the third vaccination was significantly associated with a lower risk for COVID-19-related death (OR 0.26; 95% CI 0.01 to 0.73). - Conclusions: Our cross-sectional data of COVID-19 infections in patients with IRD showed a significant reduction of hospitalisation due to infection in double-vaccinated or triple-vaccinated patients compared with those without vaccination and even a significant reduction of COVID-19-related deaths in triple-vaccinated patients. These data strongly support the beneficial effect of COVID-19 vaccination in patients with IRD. - Trial registration number EuDRACT 2020-001958-21.
DOI:doi:10.1136/rmdopen-2023-002998
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1136/rmdopen-2023-002998
 Volltext: https://rmdopen.bmj.com/content/9/2/e002998
 DOI: https://doi.org/10.1136/rmdopen-2023-002998
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:antirheumatic agents
 COVID-19
 inflammation
 vaccination
K10plus-PPN:1850953406
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69089257   QR-Code

zum Seitenanfang